Pacios, OlgaHerrera-Espejo, SorayaArmán, LucíaIbarguren-Quiles, ClaraBlasco, LucíaBleriot, InésFernández-García, LauraOrtiz-Cartagena, ConchaPaniagua, MaríaBarrio-Pujante, AntonioAracil, BelenCisneros, José MiguelPachón-Ibáñez, María EugeniaTomás, María2025-03-182025-03-182024-08-28Pacios O, Herrera-Espejo S, Armán L, Ibarguren-Quiles C, Blasco L, Bleriot I, Fernández-García L, Ortiz-Cartagena C, Paniagua M, Barrio-Pujante A, Aracil B, Cisneros JM, Pachón-Ibáñez ME, Tomás M. Mitomycin C as an Anti-Persister Strategy against Klebsiella pneumoniae: Toxicity and Synergy Studies. Antibiotics (Basel). 2024 Aug 28;13(9):815.https://hdl.handle.net/20.500.12105/26516The combination of several therapeutic strategies is often seen as a good way to decrease resistance rates, since bacteria can more easily overcome single-drug treatments than multi-drug ones. This strategy is especially attractive when several targets and subpopulations are affected, as it is the case of Klebsiella pneumoniae persister cells, a subpopulation of bacteria able to transiently survive antibiotic exposures. This work aims to evaluate the potential of a repurposed anticancer drug, mitomycin C, combined with the K. pneumoniae lytic phage vB_KpnM-VAC13 in vitro and its safety in an in vivo murine model against two clinical isolates of this pathogen, one of them exhibiting an imipenem-persister phenotype. At the same time, we verified the absence of toxicity of mitomycin C at the concentration using the human chondrocyte cell line T/C28a2. The viability of these human cells was checked using both cytotoxicity assays and flow cytometry.engVoRhttp://creativecommons.org/licenses/by/4.0/K. pneumoniaeCytotoxicityLyticphageMitomycin CPersistenceRepurposingAttribution 4.0 International3933498913981510.3390/antibiotics130908152079-6382Antibiotics (Basel, Switzerland)open access